Combination antiretroviral therapy: Materials
Materials it needs
The commodities and chemicals it needs per unit, its share of each one's demand and how critical each is
Made of- API Small-molecule APIs criticality medium The active drug ingredients are made largely by generic producers in a few countries with pharmaceutical capacity, such as India, Brazil and Thailand [4].
- KSM Pharma starting materials and intermediates criticality medium The active ingredients are built from key starting materials and intermediates bought from fine-chemical makers.
- Exc Pharmaceutical excipients criticality low Fillers and binders turn the active ingredients into tablets, including fixed-dose combinations [1].
as of 2026-11-11. No source gives amounts; criticality is the writer's judgement from the concentration of generic production.
Critical materials
The materials whose supply could hold it back
- Active ingredients: low prices rest on generic production in a few countries with pharmaceutical capacity, such as India, Brazil and Thailand [4].
- Patents: as resistance grows or better drugs arrive, patients must move to newer drugs that are still under patent and cost more [4].
- Funding: in 2025, US$ 17.6 billion was available for the AIDS response in low- and middle-income countries, about 20% below the US$ 21.9 billion needed each year by 2030 [2].
as of 2026-11-11
Sources
- Antiretroviral Drug Discovery and Development National Institute of Allergy and Infectious Diseases (NIH)
- Fact sheet 2026 UNAIDS, 2026
- The impact of patents on access to medicines MSF Access Campaign (Médecins Sans Frontières), 2017